This document is an excerpt from the EUR-Lex website
Document 02020R1737-20201123
Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)Text with EEA relevance
Consolidated text: Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)Text with EEA relevance
Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)Text with EEA relevance
- Date of document:
- 23/11/2020
- Date of effect:
- 23/11/2020
- Author:
- Not available
- Form:
- Consolidated text
- Link
- Link
- Link
- Select all documents mentioning this document
- Consolidation: basic act:
- 32020R1737
02020R1737 — EN — 23.11.2020 — 000.002
This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document
|
COMMISSION DELEGATED REGULATION (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (OJ L 392 23.11.2020, p. 1) |
Corrected by:
COMMISSION DELEGATED REGULATION (EU) 2020/1737
of 14 July 2020
amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances
(Text with EEA relevance)
Article 1
Amendments to Regulation (EC) No 273/2004
Annexes I and II to Regulation (EC) No 273/2004 are amended in accordance with Annex I to this Regulation.
Article 2
Amendments to Regulation (EC) No 111/2005
The Annex to Regulation (EC) No 111/2005 is amended in accordance with Annex II to this Regulation.
Article 3
Entry into force and application
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Point (1)(b) and point (2) of Annex I and point (2)(b) of Annex II shall apply from 13 January 2021.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
ANNEX I
Annexes I and II to Regulation (EC) No 273/2004 are amended as follows:
Annex I is amended as follows:
the table ‘CATEGORY 1’ is amended as follows:
the entry for Alpha-phenylacetoacetonitrile is replaced by the following:
|
Substance |
CN designation (if different) |
CN Code |
CAS No |
|
‘Alpha-phenylacetoacetonitrile (APAAN) |
|
2926 40 00 |
4468-48-8’ |
in the entry for (1R,2S)-(-)-chloroephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1S,2R)-(+)-chloroephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1S,2S)-(+)-chloropseudoephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1R,2R)-(-)-chloropseudoephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
the following entries are inserted in the appropriate place sequentially according to the CN Code:
|
Substance |
CN designation (if different) |
CN Code |
CAS No |
|
‘Methyl 3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (PMK methyl glycidate) |
|
2932 99 00 |
13605-48-6 |
|
3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylic acid (PMK glycidic acid) |
|
2932 99 00 |
2167189-50-4 |
|
Alpha-phenylacetoacetamide (APAA) |
|
2924 29 70 |
4433-77-6 |
|
Methyl 2-methyl-3-phenyloxirane-2-carboxylate (BMK methyl glycidate) |
|
2918 99 90 |
80532-66-7 |
|
2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) |
|
2918 99 90 |
25547-51-7 |
|
Methyl alpha-phenylacetoacetate (MAPA) |
|
2918 30 00 |
16648-44-5’ |
in the table ‘SUBCATEGORY 2A’, the following entry is inserted in the appropriate place sequentially according to the CN Code:
|
Substance |
CN designation (if different) |
CN Code |
CAS No. |
|
‘Red phosphorus |
|
2804 70 00 |
7723-14-0’ |
in the entry for Anthranilic acid in the table ‘SUBCATEGORY 2B’, the CN code ‘2922 43 00 ’ is replaced by ‘2922 43 00 ’;
in the entry for Sulphuric acid in the table ‘CATEGORY 3’, the CN code ‘2807 00 10 ’ is replaced by ‘2807 00 00 ’;
in the table in Annex II, the following entry is added:
|
Substance |
Threshold |
|
‘Red phosphorus |
0,1 kg’ |
ANNEX II
The Annex to Regulation (EC) No 111/2005 is amended as follows:
the table ‘CATEGORY 1’ is amended as follows:
the entry for Alpha-phenylacetoacetonitrile is replaced by the following:
|
Substance |
CN designation (if different) |
CN Code |
CAS No |
|
‘Alpha-phenylacetoacetonitrile (APAAN) |
|
2926 40 00 |
4468-48-8’ |
in the entry for (1R,2S)-(-)-chloroephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1S,2R)-(+)-chloroephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1S,2S)-(+)-chloropseudoephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
in the entry for (1R,2R)-(-)-chloropseudoephedrine, the CN code ‘2939 99 00 ’ is replaced by ‘2939 79 90 ’;
the following entries are inserted in the appropriate place sequentially according to the CN Code:
|
Substance |
CN designation (if different) |
CN Code |
CAS No |
|
‘Methyl 3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (PMK methyl glycidate) |
|
2932 99 00 |
13605-48-6 |
|
3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylic acid (PMK glycidic acid) |
|
2932 99 00 |
2167189-50-4 |
|
Alpha-phenylacetoacetamide (APAA) |
|
2924 29 70 |
4433-77-6 |
|
Methyl 2-methyl-3-phenyloxirane-2-carboxylate (BMK methyl glycidate) |
|
2918 99 90 |
80532-66-7 |
|
2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) |
|
2918 99 90 |
25547-51-7 |
|
Methyl alpha-phenylacetoacetate (MAPA) |
|
2918 30 00 |
16648-44-5’ |
the table ‘Category 2’ is amended as follows:
in the entry for Anthranilic acid in, the CN code ‘2922 43 00 ’ is replaced by ‘2922 43 00 ’;
the following entry is inserted in the appropriate place sequentially according to the CN Code:
|
Substance |
CN designation (if different) |
CN Code |
CAS No. |
|
‘Red phosphorus |
|
2804 70 00 |
7723-14-0’ |
in the entry for Sulphuric acid in the table ‘Category 3’, the CN code ‘2807 00 10 ’ is replaced by ‘2807 00 00 ’;
the table ‘Category 4’ is amended as follows:
in the entry for medicinal products and veterinary medicinal products containing ephedrine or its salts, the CN code ‘3003 40 20’ is replaced by ‘3003 41 00 ’ and the CN code ‘3004 40 20’ is replaced by ‘3004 41 00 ’;
in the entry for medicinal products and veterinary medicinal products containing pseudoephedrine or its salts, the CN code ‘3003 40 30’ is replaced by ‘3003 42 00 ’ and the CN code ‘3004 40 30’ is replaced by ‘3004 42 00 ’.
